2022 NP Network Event (NP Ball)
On November 12, 2022 the NP Council of NNPBC is delighted to host the inaugural NP Networking Event ("NP Ball") at the Royal Vancouver Yacht Club, Vancouver, BC.
This will be an education and networking event that will bring together nurse practitioners during National Nurse Practitioner week. Through survey feedback, mentorship was identified as a priority for NPs. To meet this priority, Dr. David Wood will deliver a keynote speech addressing the importance of mentoring and modeling professionalism in clinical care. A networking opportunity will also be organized to strengthen our community connections and collegiality.
A professional photographer will be on site providing head shots during the networking segment.
Date: Saturday November 12, 2022
Venue: Royal Vancouver Yacht Club
3811 Point Grey Rd, Vancouver BC (main level)
Time: 4:30 pm - 12:00 am
Cost: $120 / ticket regular NP member and guests,
$89 / student NP members
$89 / student NP members
Dinner: Three course dinner with wine options
Dress code: Formal
Drinks available for purchase (Credit and debit only)
Ticket Sales Closed at 5pm on November 5, 2022.
Event Learning Objectives
- Enhance knowledge and understanding of the importance of mentorship and professionalism as a health care leader
- Sharpen leadership skills through collaboration and networking with internal and external partners
Program
| 4:30pm - 6:30pm | NP networking, professional head shots and industry engagement |
| 7:00pm - 8:00pm | Presentations
|
| 7:00pm - 9:00pm | Dinner |
| 9:00pm - 12:00am | Live DJ, dancing and photobooth |
Please reach out to Parveen Sangha (NP Ball Chair) psangha@nnpbc.com or Sukhi Jassar (NP Ball Executive Liaison) sjassar@nnpbc.com if you have any questions.
X
Login to NNPBC
X
Dr. David Wood
Dr. David Wood is a Professor of Medicine at the University of British Columbia (UBC). He is the Head of the Division of Cardiology and the Medical Director for the Cardiac Sciences Program at Vancouver Coastal Health. He is the inaugural Director of the new UBC Centre for Cardiovascular Innovation – Centre d'Innovation Cardiovasculaire (CCI-CIC), a clinical research operation centre with 41 affiliated staff and more than 90 cardiovascular investigators in British Columbia. Dr. Wood is the President of the Canadian Association of Interventional Cardiology (CAIC-ACCI). He received the Luminary Award at the recent C3 Global Submit. He is the Course Director for both the annual CAIC-ACCI Summit and Vancouver Valve global meetings where attendees present problems, offer solutions, and debate innovations with the end goal of improving patient care for all patients with structural heart disease. Dr. Wood is passionate about mentoring the next generation cardiovascular clinicians.
Dr. Wood works as a structural and interventional cardiologist at Vancouver General and St. Paul's Hospital. He obtained subspecialty training at Lenox Hill Heart and Vascular Institute of New York. His primary research interests include transcatheter management of structural and valvular heart disease, new device development, novel strategies for treating ACS, and advanced cardiac imaging. Dr. Wood has participated in over 50 live-cases and 20 first-in-human cases. Has co-authored over 300 publications which have been cited > 9000 times (h-index 55) and his work has been cited in all the major coronary artery and structural heart disease guidelines.
He recently published the 3M TAVR Study (JACC CVI), the SAFE MANTA Study (Circ CVI), and was co-principal investigator of the CIHR funded COMPLETE trial (4,041 patients, 140 centres, 31 countries) that was presented as Late Breaking Science at both ESC and TCT with simultaneous publication in NEJM and JACC. He is currently PI of the following investigator-initiated studies: the COMPLETE TAVR trial (n = 4000, 126 centres), the DISCORDANCE TAVR study (n = 50, 11 centres), the ULTRA CLOSURE study (n = 250, 7 centres), the PROTECT TAVR study (n = 130, 11 centres), and the SAFE TAVR study (n = 415, 15 centres). In May 2020, in collaboration with 15 North American Cardiovascular Society Leaders representing over 90,000 clinicians, he simultaneously published Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic in JACC, CJC, and the ATS.
Dr. Wood works as a structural and interventional cardiologist at Vancouver General and St. Paul's Hospital. He obtained subspecialty training at Lenox Hill Heart and Vascular Institute of New York. His primary research interests include transcatheter management of structural and valvular heart disease, new device development, novel strategies for treating ACS, and advanced cardiac imaging. Dr. Wood has participated in over 50 live-cases and 20 first-in-human cases. Has co-authored over 300 publications which have been cited > 9000 times (h-index 55) and his work has been cited in all the major coronary artery and structural heart disease guidelines.
He recently published the 3M TAVR Study (JACC CVI), the SAFE MANTA Study (Circ CVI), and was co-principal investigator of the CIHR funded COMPLETE trial (4,041 patients, 140 centres, 31 countries) that was presented as Late Breaking Science at both ESC and TCT with simultaneous publication in NEJM and JACC. He is currently PI of the following investigator-initiated studies: the COMPLETE TAVR trial (n = 4000, 126 centres), the DISCORDANCE TAVR study (n = 50, 11 centres), the ULTRA CLOSURE study (n = 250, 7 centres), the PROTECT TAVR study (n = 130, 11 centres), and the SAFE TAVR study (n = 415, 15 centres). In May 2020, in collaboration with 15 North American Cardiovascular Society Leaders representing over 90,000 clinicians, he simultaneously published Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic in JACC, CJC, and the ATS.
X
2022 NP Network Event Sponsor
At Eisai Canada, human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. Eisai operates in two global business groups: oncology and neurology (dementia-related diseases, insomnia, epilepsy and neurodegenerative diseases).
Eisai Canada
At Eisai Canada, human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. Eisai operates in two global business groups: oncology and neurology (dementia-related diseases, insomnia, epilepsy and neurodegenerative diseases).X
2022 NP Network Event Sponsor
Snore MD is a locally owned and operated Sleep Clinic with 25+ years of experience providing exceptional patient care. Our sleep clinics are made up of highly skilled medical professionals that focus on ensuring a patient-centred approach. This includes patient education, delivering unmatched patient care, ease of access, and sharing innovative technology focused on sleep apnea solutions. Snore MD excels in working collaboratively with healthcare professionals, including family physicians, nurse practitioners, specialists, and respiratory therapists, in improving the health and well-being of every patient suffering from obstructive sleep apnea.
Snore MD
Snore MD is a locally owned and operated Sleep Clinic with 25+ years of experience providing exceptional patient care. Our sleep clinics are made up of highly skilled medical professionals that focus on ensuring a patient-centred approach. This includes patient education, delivering unmatched patient care, ease of access, and sharing innovative technology focused on sleep apnea solutions. Snore MD excels in working collaboratively with healthcare professionals, including family physicians, nurse practitioners, specialists, and respiratory therapists, in improving the health and well-being of every patient suffering from obstructive sleep apnea.X
2022 NP Network Event Sponsor
HLS Therapeutics is dedicated to introducing novel therapies and keeping trusted branded drugs on the market.
HLS provides access to medications critical to physicians, patients, and their caregivers with the high-quality brand names they trust.
HLS Therapeutics
HLS Therapeutics is dedicated to introducing novel therapies and keeping trusted branded drugs on the market.HLS provides access to medications critical to physicians, patients, and their caregivers with the high-quality brand names they trust.
X
2022 NP Network Event Sponsor
Victoria Primary Care Network is a growing community of primary care providers and allied health professionals working collaboratively to provide longitudinal patient-centered care.
We value nurse practitioners as important members of our team-based care strategy and invite you to connect with us about meaningful career opportunities in Urban Victoria.
Victoria Primary Care Network
Victoria Primary Care Network is a growing community of primary care providers and allied health professionals working collaboratively to provide longitudinal patient-centered care.
We value nurse practitioners as important members of our team-based care strategy and invite you to connect with us about meaningful career opportunities in Urban Victoria.X
2022 NP Network Event Sponsor
Delivering Innovative Products to the Canadian Market
Medexus Pharma Canada is a Canadian-based specialty pharmaceutical company focused on the key areas of rheumatology, auto-immune disease, pediatrics, allergy, and dermatology. The company manages the licensing, registration, marketing, sales, and distribution of several innovative pharmaceutical products in Canada.
Medexus Pharma Canada leverages its extensive market knowledge and strong Canadian position as an innovator with new and existing products to deliver clinically proven safe and effective brands and consistent product value.
Medexus Pharma Canada
Delivering Innovative Products to the Canadian MarketMedexus Pharma Canada is a Canadian-based specialty pharmaceutical company focused on the key areas of rheumatology, auto-immune disease, pediatrics, allergy, and dermatology. The company manages the licensing, registration, marketing, sales, and distribution of several innovative pharmaceutical products in Canada.
Medexus Pharma Canada leverages its extensive market knowledge and strong Canadian position as an innovator with new and existing products to deliver clinically proven safe and effective brands and consistent product value.
X
2022 NP Network Event Sponsor
At Novartis, our mission of caring and curing underscores our work, our values and our efforts around the world. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Novartis
At Novartis, our mission of caring and curing underscores our work, our values and our efforts around the world. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.X
2022 NP Network Event Sponsor
AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. Our core scientific focus is in the areas of Cardiovascular, Renal and Metabolism. The company employs more than 1,200 people across Canada, including 700 employees at our head office and clinical research hub in Mississauga, Ontario.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. Our core scientific focus is in the areas of Cardiovascular, Renal and Metabolism. The company employs more than 1,200 people across Canada, including 700 employees at our head office and clinical research hub in Mississauga, Ontario.X
2022 NP Network Event Sponsor
Aspen Pharmacare Canada, a branch of Aspen Holdings founded in 2014, is a South African-based supplier of branded and generic pharmaceuticals in more than 150 countries across the world, providing products renowned for their quality, efficacy and affordability.
In Canada, Aspen’s focus is on the following therapeutic areas:
Aspen Pharmacare Canada
Aspen Pharmacare Canada, a branch of Aspen Holdings founded in 2014, is a South African-based supplier of branded and generic pharmaceuticals in more than 150 countries across the world, providing products renowned for their quality, efficacy and affordability.In Canada, Aspen’s focus is on the following therapeutic areas:
- Women's Health - Linessa®
- Anesthesia – EMLA®, Xylocaine®, Sensorcaine®, Naropin®, Diprivan®
- Anti-Infectives - Septra®
- Thrombosis - Arixtra®, Orgaran®
- Endocrinology - Eltroxin®
- Oncology - Alkeran®, Myleran®, Lanvis®, Leukeran®
X
2022 NP Network Event Sponsor
A Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology. Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and its manufacturing facility is located in Varennes, Québec, Canada.
Miravo
A Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology. Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and its manufacturing facility is located in Varennes, Québec, Canada.